These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15161438)

  • 21. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
    Grant S
    Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
    [No Abstract]   [Full Text] [Related]  

  • 22. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
    Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
    Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of signaling in myelodysplastic syndrome.
    Gore SD
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):613-22. PubMed ID: 15494298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic agents in acute myeloid leukemia.
    Stone RM
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):163-6. PubMed ID: 17379102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia.
    Mikesch JH; Steffen B; Berdel WE; Serve H; Müller-Tidow C
    Leukemia; 2007 Aug; 21(8):1638-47. PubMed ID: 17554387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of older patients with acute myeloid leukemia--new agents.
    Burnett AK; Mohite U
    Semin Hematol; 2006 Apr; 43(2):96-106. PubMed ID: 16616043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retinoic acid signaling in myelopoiesis.
    Drumea K; Yang ZF; Rosmarin A
    Curr Opin Hematol; 2008 Jan; 15(1):37-41. PubMed ID: 18043244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deregulation of signaling pathways in acute myeloid leukemia.
    Scholl C; Gilliland DG; Fröhling S
    Semin Oncol; 2008 Aug; 35(4):336-45. PubMed ID: 18692684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical aspects and therapeutic perspectives of acute and chronic leukemias.
    Hiddemann W; Griesinger F
    Curr Opin Oncol; 1993 Jan; 5(1):13-25. PubMed ID: 8427885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to epidermal growth factor receptor-targeted therapy.
    Morgillo F; Lee HY
    Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in the treatment of acute myeloid leukemia.
    Ravandi F; Burnett AK; Agura ED; Kantarjian HM
    Cancer; 2007 Nov; 110(9):1900-10. PubMed ID: 17786921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic myeloid leukemia].
    Udvardy M
    Orv Hetil; 2005 Feb; 146(6):243-7. PubMed ID: 15779811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new class of anti-cancer drugs: HDAC-inhibitors.
    Pelicci PG
    Suppl Tumori; 2002; 1(4):S66. PubMed ID: 12415827
    [No Abstract]   [Full Text] [Related]  

  • 37. [Tyrosine kinase inhibitors (TKI), a concept and acronym of the future].
    Dubreuil P
    Med Sci (Paris); 2003 Feb; 19(2):133-5. PubMed ID: 12836602
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeted Therapeutic Approach Based on Understanding of Aberrant Molecular Pathways Leading to Leukemic Proliferation in Patients with Acute Myeloid Leukemia.
    Song MK; Park BB; Uhm JE
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071627
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.
    Reikvam H; Hoang TT; Bruserud Ø
    Expert Rev Hematol; 2015 Jun; 8(3):315-27. PubMed ID: 25901742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Recent topics on leukemia: New molecular targeting therapy].
    Hirai H
    Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):1036-42. PubMed ID: 12866451
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.